Newsletter February 2026

Welcoming new voices to our Clinical Advisory Group

We are proud to announce the new members of our Clinical Advisory Group.

•  Dr Ashish Narula is a Consultant Histopathologist and Clinical Director of Pathology, bringing expert leadership in uropathology, prostate cancer diagnostics, and evidence-based pathology practice to support high-quality prostate cancer care.
• Alex Freeman is a Consultant Urological Pathologist at UCLH with over 20 years experience in tertiary cancer care, specialising in prostate, bladder and penile cancers and supporting multidisciplinary clinical decision-making.
• Tharshini Ramalingam is a board-certified cardio-oncology specialist and GP, combining expertise across cardiology, oncology and primary care to champion holistic, patient-centred care for people living with cancer and cardiovascular disease.
• Thomas Charlton is a Consultant Clinical Oncologist at The Royal Marsden Hospital, specialising in radiotherapy and systemic treatments for prostate cancer.
• Dr Deep Chakrabarti is a Consultant Clinical Oncologist specialising in uro-oncology, with a particular focus on prostate cancer.

Our Clinical Advisory Group (CAG) is an expert-led multidisciplinary panel, from urologists and oncologists to nurses and GPs brought together to help shape better care for men with prostate cancer. Launched in late 2022, the group meets quarterly to advise and support the charity’s strategic work, offering real-world clinical insight on crucial topics like early diagnosis, active surveillance and PSA testing. Their guidance helps improve care delivery across the UK and informs key decisions that impact patients and healthcare professionals alike.

Empowering men through movement: Two Exercise as Medicine pilots successfully delivered

Empowering men through movement: Two Exercise as Medicine pilots successfully delivered

We are delighted to share the successful completion of two 12-week Exercise as Medicine pilots delivered across two sites in partnership with Prostate Cancer UK. Designed as a quality improvement programme for men diagnosed with prostate cancer within the past year, the pilots combined structured, supervised exercise with tailored patient education to support physical health, wellbeing and confidence during active treatment and beyond.

Participants took part in weekly physical activity sessions led by specialist professionals, alongside educational sessions covering treatments, side effects, nutrition and support for loved ones. Feedback and quality-of-life measures collected before, during and after the programme highlighted strong engagement and positive experiences, reinforcing the growing evidence that exercise can help men better tolerate treatment, manage side effects and feel more empowered in their care.

The success of these pilots marks an important step in strengthening evidence-informed exercise support for men with prostate cancer and will help shape future delivery and wider rollout of similar programmes.

Exercise as Medicine Hub webpages for healthcare professionals coming soon...watch this space! 

UK's Prostate Cancer Clinical Research Strategy Group (CRSG)

Following the wind-down of the National Cancer Research Institute (NCRI), the former NCRI Prostate Group has been re-established as the UK Prostate Cancer Clinical Research Strategy Group (CRSG).

The CRSG’s purpose is to identify key research gaps that matter to men affected by prostate cancer, help shape and strengthen the UK prostate cancer research landscape, and support high-quality clinical research by offering expert guidance and constructive feedback early in study design and development.

By providing input at an early stage, the group aims to improve the quality, feasibility, and competitiveness of research proposals before they are submitted for funding or approval.

We welcome proposals for clinical trials and will also consider translational or biomarker research with a clear clinical line of sight. Proposals focused solely on basic science are not within scope.

Get in touch at [email protected].

Deadline: 4pm Friday 13 February.

Find out more and apply

UK NSC Supports Targeted Prostate Cancer Screening for BRCA Gene Carriers

The UK National Screening Committee has announced its support for a targeted prostate cancer screening programme for men with BRCA gene variations, following a review of the latest evidence on PSA testing and targeted screening approaches. This marks an important step toward earlier diagnosis for men with an inherited genetic risk of prostate cancer.

While we welcome this progress, we are disappointed that screening has not been extended to the wider high-risk population, including Black men and those with a family history of prostate cancer, where the need for earlier detection remains urgent.

As implementation of the programme will take time, healthcare professionals continue to play a vital role in supporting men to understand their risk, make informed decisions about PSA testing, and manage diagnosis, treatment, side effects and long-term care—particularly for men at higher risk.

You can read our full statement, co-signed by the Royal College of Physicians and Surgeons of Glasgow, the British Association of Urological Surgeons and other key stakeholders.

View co-signed statement

Don’t delay! Sign up today for the Specialists Conference 2026.

A free, two-morning online event where leading experts will share the latest insights and best practice in prostate cancer care. 

When: Wednesday 25 – Thursday 26 March 2026
Where: Online 

Time: 9:00am to 12:30pm 

If you can’t join us live, you can still sign up to access the recordings afterwards.  

Sign up